Long-term efficacy and safety of onabotulinumtoxinA in patients with urinary incontinence due to neurogenic detrusor overactivity: An interim analysis

Urology

Volumn 81, Issue 3, 2013, Pages 491-497

  Kennelly, Michael ^a   Dmochowski, Roger ^b   Ethans, Karen ^b   Karsenty, Gilles ^b   Schulte Baukloh, Heiner ^b   Jenkins, Brenda ^b   Thompson, Catherine ^b   Li, Daniel ^b   Haag Molkenteller, Cornelia ^b  

^a Carolinas Rehabilitation ^*  (United States)

^b Carolinas Rehabilitation   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BOTULINUM TOXIN A; CHOLINERGIC RECEPTOR BLOCKING AGENT;

ARTICLE; BLADDER CATHETERIZATION; CENTRAL NERVOUS SYSTEM FUNCTION; CONSTIPATION; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG SAFETY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; FALLING; FATIGUE; FEVER; HEMATURIA; HUMAN; INCONTINENCE QUALITY OF LIFE SCORE; LONG TERM CARE; NEUROGENIC BLADDER; OUTCOME ASSESSMENT; OVERACTIVE BLADDER; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; REPEAT PROCEDURE; SCORING SYSTEM; SIDE EFFECT; URINARY TRACT INFECTION; URINE INCONTINENCE; URINE RETENTION; URINE VOLUME;

BOTULINUM TOXINS, TYPE A; FEMALE; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; TIME FACTORS; URINARY BLADDER, NEUROGENIC; URINARY BLADDER, OVERACTIVE; URINARY INCONTINENCE;

EID: 84875366255     PISSN: 00904295     EISSN: 15279995     Source Type: Journal    
DOI: 10.1016/j.urology.2012.11.010     Document Type: Article

References (11)

1. B. Schurch, M. Stöhrer, and G. Kramer Botulinum-A toxin for treating detrusor hyperreflexia in spinal cord injured patients: a new alternative to anticholinergic drugs? Preliminary results J Urol 164 2000 692 697
2. F. Cruz, S. Herschorn, and P. Aliotta Efficacy and safety of onabotulinumtoxinA in patients with urinary incontinence due to neurogenic detrusor overactivity: a randomised, double-blind, placebo-controlled trial Eur Urol 60 2011 742 750
3. D. Ginsberg, A. Gousse, and V. Keppenne Phase 3 efficacy and tolerability study of onabotulinumtoxinA in patients with urinary incontinence resulting from neurogenic detrusor overactivity J Urol 187 2012 2131 2139
4. D.L. Patrick, M.L. Martin, and D.M. Bushnell Quality of life of women with urinary incontinence: further development of the incontinence quality of life instrument (I-QOL) Urology 53 1999 71 76
5. C.L. Hatheway, and C. Dang Immunogenicity of the neurotoxins of Clostridium botulinum J. Jankovic, M. Hallett, Therapy with Botulinum Toxin 1994 Marcel Dekker New York 93 107
6. B. Schurch, P. Denys, and C.M. Kozma Reliability and validity of the Incontinence Quality of Life questionnaire in patients with neurogenic urinary incontinence Arch Phys Med Rehabil 88 2007 646 652
7. A. Manack, S.P. Motsko, and C. Haag-Molkenteller Epidemiology and healthcare utilization of neurogenic bladder patients in a US claims database Neurourol Urodyn 30 2011 395 401
8. M.F. Brin, C.L. Comella, J. Jankovic CD-017 BoNTA Study Group Long-term treatment with botulinum toxin type A in cervical dystonia has low immunogenicity by mouse protection assay Mov Disord 23 2008 1353 1360
9. K. Müller, E. Mix, and F. Adib Saberi Prevalence of neutralising antibodies in patients treated with botulinum toxin type A for spasticity J Neural Transm 116 2009 579 585
10. ®) across multiple indications Mov Disord 25 2010 2211 2218
11. M.Z. Atassi Basic immunological aspects of botulinum toxin therapy Mov Disord 19 2004 S68 S84